MAPT and Alzheimer disease: The available evidence shows that these drugs seem to have only a symptomatic effect, and only recently an interplay between them and the putative neuropathogenic mechanisms of AD, namely amyloid aggregation, tau phosphorylation, and neuroinflammation, has been investigated.